OLIGOMYCIN B Chemical Properties

Melting point:

160-161℃

Boiling point:

911.4±65.0 °C(Predicted)

Density 

1.19 g/cm3

storage temp. 

−20°C

solubility 

≤30mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide

pka

12.52±0.70(Predicted)

form 

White to off-white powder.

Merck 

13,6902

Safety Information

Hazard Codes 

Xn,T

Risk Statements 

20/21/22-68/20/21/22-22

Safety Statements 

36/37

RIDADR 

2811

WGK Germany 

3

RTECS 

RK3330000

F 

3-10

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

29419090

MSDS

• Language:English Provider:SigmaAldrich

OLIGOMYCIN B Usage And Synthesis

Description

Oligomycins are macrolides created by Streptomyces species that can be toxic to other organisms. Different oligomycin isomers are highly specific for the disruption of mitochondrial metabolism. Oligomycin B is a nonselective inhibitor of the mitochondrial F₁F_O ATP synthase. Oligomycin B (1-10 μM) can reduce the rate of ATP depletion in myocardial ischemia and decrease calcium-induced calcium release oscillation frequency of rat sensory neurons.

Uses

Oligomycin B, a minor component of the oligomycin complex isolated from selected strains of Streptomyces, is an inhibitor of mitochondrial F1F0-ATPase. It makes cells more susceptible to cell death, and also leads to a switch in the death mode from apoptosis to necrosis.

Uses

Oligomycin B is an antibiotic that acts as a nonselective inhibitor of ATP synthase.

in vitro

previous study found that oligomycin b and aurovertin b were able to inhibit both the synthase and the hydrolase function, which not only rendered them difficult to be experimentally used, but also precluded them from being therapeutics. aurovertin b bound between the subunits catalytic f1 domain of the f1f0 atpase, where it prevented the conformational changes required for the catalytic cycle of this enzyme, whereas oligomycin bound to the f0 domain and blocked proton flow [1].

in vivo

in a previous animal study, intracranial pressure measurements were performed in sd rats treated by intraperitoneal injection of vehicle, cyclosporine a, or oligomycin b. it was found that cerebral edema and mitochondrial impairment could be significantly worsened by treatment with oligomycin b, whereas a noticeable improvement could be observed in animals that received injections of cyclosporine a [2].

References

[1] g. j. grover and j. malm. pharmacological profile of the selective mitochondrial f1f0 atp hydrolase inhibitor bms-199264 in myocardial ischemia. cardiovasc.ther. 26, 287-296 (2008).
[2] vlodavsky e, palzur e, shehadeh m, soustiel jf. post-traumatic cytotoxic edema is directly related to mitochondrial function. j cereb blood flow metab. 2017 jan;37(1):166-177.

OLIGOMYCIN B(11050-94-5)Related Product Information

• 2,6-HEPTANEDIONE
• TRANS-2-OCTENOIC ACID
• 8,10-DODECADIEN-1-OL
• OLIGOMYCIN B
• 3-Hydroxy-3-methyl-2-butanone
• 1,7-DIOXASPIRO[5.5]UNDECANE
• ISOOCTYL ACRYLATE
• N-OCTYL ACRYLATE
• 2-UNDECENOIC ACID
• METHYL 4-METHYL-2-PENTENOATE
• ETHYL TRANS-2-OCTENOATE
• Methyl trans-2-nonenoate
• 3,3-Dimethoxybutan-2-one
• N-HEPTYL ACRYLATE
• 2,4-DIMETHYL-3-HEPTANONE
• OLIGOMYCIN
• oligomycin D
• OLIGOMYCIN A